Clinical Pharmacology & Therapeutics - Issue - nature.com science feeds Clinical Pharmacology & Therapeutics, the most cited journal publishing primary investigation in pharmacology and pharmacy, is the authoritative, cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy and evaluation of therapeutics. http://www.nature.com/clpt/current_issue/ Nature Publishing Group en Copyright © Nature Publishing Group Clinical Pharmacology & Therapeutics 0009-9236 Copyright © Nature Publishing Group permissions@nature.com Clinical Pharmacology & Therapeutics http://www.nature.com/aj/images/logos_b_o_w/clpt.gif http://www.nature.com/clpt/ In This Issue http://feeds.nature.com/~r/clpt/rss/current/~3/LT37QCBxMoU/clpt.2009.202 In This Issue

Clinical Pharmacology & Therapeutics 86, 451 (November 2009). doi:10.1038/clpt.2009.202

]]> In This Issue doi:10.1038/clpt.2009.202 Clinical Pharmacology & Therapeutics 86, 451 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.202 http://dx.doi.org/10.1038/clpt.2009.202 86 5 451 451 http://dx.doi.org/10.1038/clpt.2009.202 Nephropharmacology: Drugs and the Kidney http://feeds.nature.com/~r/clpt/rss/current/~3/HUzMZ2S05N0/clpt.2009.191 Nephropharmacology: Drugs and the Kidney

Clinical Pharmacology & Therapeutics 86, 453 (November 2009). doi:10.1038/clpt.2009.191

Authors: A J Atkinson & S-M Huang

]]> Nephropharmacology: Drugs and the Kidney A J Atkinson S-M Huang doi:10.1038/clpt.2009.191 Clinical Pharmacology & Therapeutics 86, 453 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.191 http://dx.doi.org/10.1038/clpt.2009.191 86 5 453 456 http://dx.doi.org/10.1038/clpt.2009.191 Highlights http://feeds.nature.com/~r/clpt/rss/current/~3/3jQlCTJGQD0/clpt.2009.203 Highlights

Clinical Pharmacology & Therapeutics 86, 458 (November 2009). doi:10.1038/clpt.2009.203

Author:

]]> Highlights doi:10.1038/clpt.2009.203 Clinical Pharmacology & Therapeutics 86, 458 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.203 http://dx.doi.org/10.1038/clpt.2009.203 86 5 458 459 http://dx.doi.org/10.1038/clpt.2009.203 ASCPT News http://feeds.nature.com/~r/clpt/rss/current/~3/5QihXDcwyKA/clpt.2009.196 ASCPT News

Clinical Pharmacology & Therapeutics 86, 460 (November 2009). doi:10.1038/clpt.2009.196

]]> ASCPT News doi:10.1038/clpt.2009.196 Clinical Pharmacology & Therapeutics 86, 460 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.196 http://dx.doi.org/10.1038/clpt.2009.196 86 5 460 461 http://dx.doi.org/10.1038/clpt.2009.196 Clinical Physiology and Pharmacology: The Essentials http://feeds.nature.com/~r/clpt/rss/current/~3/WzYd9EqtByg/clpt.2009.189 Clinical Physiology and Pharmacology: The Essentials

Clinical Pharmacology & Therapeutics 86, 462 (November 2009). doi:10.1038/clpt.2009.189

Author: M J Avram

]]> Clinical Physiology and Pharmacology: The Essentials M J Avram doi:10.1038/clpt.2009.189 Clinical Pharmacology & Therapeutics 86, 462 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.189 http://dx.doi.org/10.1038/clpt.2009.189 86 5 462 463 http://dx.doi.org/10.1038/clpt.2009.189 Use of the MDRD Study Equation to Estimate Kidney Function for Drug Dosing http://feeds.nature.com/~r/clpt/rss/current/~3/pM8YLHJVjrE/clpt.2009.124 Use of the MDRD Study Equation to Estimate Kidney Function for Drug Dosing

Clinical Pharmacology & Therapeutics 86, 465 (November 2009). doi:10.1038/clpt.2009.124

Authors: L A Stevens & A S Levey

]]> Use of the MDRD Study Equation to Estimate Kidney Function for Drug Dosing L A Stevens A S Levey doi:10.1038/clpt.2009.124 Clinical Pharmacology & Therapeutics 86, 465 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.124 http://dx.doi.org/10.1038/clpt.2009.124 86 5 465 467 http://dx.doi.org/10.1038/clpt.2009.124 Continuing the Use of the Cockcroft–Gault Equation for Drug Dosing in Patients With Impaired Renal Function http://feeds.nature.com/~r/clpt/rss/current/~3/3lNTLcExJ-k/clpt.2009.187 Continuing the Use of the Cockcroft–Gault Equation for Drug Dosing in Patients With Impaired Renal Function

Clinical Pharmacology & Therapeutics 86, 468 (November 2009). doi:10.1038/clpt.2009.187

Authors: W J Spruill, W E Wade & H H Cobb

]]> Continuing the Use of the Cockcroft–Gault Equation for Drug Dosing in Patients With Impaired Renal Function W J Spruill W E Wade H H Cobb doi:10.1038/clpt.2009.187 Clinical Pharmacology & Therapeutics 86, 468 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.187 http://dx.doi.org/10.1038/clpt.2009.187 86 5 468 470 http://dx.doi.org/10.1038/clpt.2009.187 How a US Regulator Can Encourage New Science http://feeds.nature.com/~r/clpt/rss/current/~3/fQKf340MUk4/clpt.2009.188 How a US Regulator Can Encourage New Science

Clinical Pharmacology & Therapeutics 86, 471 (November 2009). doi:10.1038/clpt.2009.188

Author: D C Throckmorton

]]> How a US Regulator Can Encourage New Science D C Throckmorton doi:10.1038/clpt.2009.188 Clinical Pharmacology & Therapeutics 86, 471 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.188 http://dx.doi.org/10.1038/clpt.2009.188 86 5 471 472 http://dx.doi.org/10.1038/clpt.2009.188 How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing? http://feeds.nature.com/~r/clpt/rss/current/~3/W4ggD0UwuTE/clpt.2009.146 How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing?

Clinical Pharmacology & Therapeutics 86, 472 (November 2009). doi:10.1038/clpt.2009.146

Authors: L G Dressler & S F Terry

]]> How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing? L G Dressler S F Terry doi:10.1038/clpt.2009.146 Clinical Pharmacology & Therapeutics 86, 472 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.146 http://dx.doi.org/10.1038/clpt.2009.146 86 5 472 475 http://dx.doi.org/10.1038/clpt.2009.146 When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective http://feeds.nature.com/~r/clpt/rss/current/~3/cMNqj2ru8Fg/clpt.2009.190 When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective

Clinical Pharmacology & Therapeutics 86, 475 (November 2009). doi:10.1038/clpt.2009.190

Authors: S-M Huang, R Temple, S Xiao, L Zhang & L J Lesko

]]> When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective S-M Huang R Temple S Xiao L Zhang L J Lesko doi:10.1038/clpt.2009.190 Clinical Pharmacology & Therapeutics 86, 475 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.190 http://dx.doi.org/10.1038/clpt.2009.190 86 5 475 479 http://dx.doi.org/10.1038/clpt.2009.190 Challenges in Developing Evidence-Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy http://feeds.nature.com/~r/clpt/rss/current/~3/3b9opwwja-4/clpt.2009.150 Challenges in Developing Evidence-Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy

Clinical Pharmacology & Therapeutics 86, 479 (November 2009). doi:10.1038/clpt.2009.150

Authors: B A Mueller & W E Smoyer

]]> Challenges in Developing Evidence-Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy B A Mueller W E Smoyer doi:10.1038/clpt.2009.150 Clinical Pharmacology & Therapeutics 86, 479 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics 10.1038/clpt.2009.150 http://dx.doi.org/10.1038/clpt.2009.150 86 5 479 482 http://dx.doi.org/10.1038/clpt.2009.150 Drug Dosing in Patients With Impaired Renal Function http://feeds.nature.com/~r/clpt/rss/current/~3/sg5zZ-79L8E/clpt.2009.135 Drug Dosing in Patients With Impaired Renal Function

Clinical Pharmacology & Therapeutics 86, 483 (November 2009). doi:10.1038/clpt.2009.135

Author: D C Brater

]]> Drug Dosing in Patients With Impaired Renal Function D C Brater doi:10.1038/clpt.2009.135 Clinical Pharmacology & Therapeutics 86, 483 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 22, 2009 10.1038/clpt.2009.135 http://dx.doi.org/10.1038/clpt.2009.135 86 5 483 489 http://dx.doi.org/10.1038/clpt.2009.135 Novel Biomarkers of Acute Kidney Toxicity http://feeds.nature.com/~r/clpt/rss/current/~3/5TicAtED2Cs/clpt.2009.149 Novel Biomarkers of Acute Kidney Toxicity

Clinical Pharmacology & Therapeutics 86, 490 (November 2009). doi:10.1038/clpt.2009.149

Authors: F M Goodsaid, M Blank, F Dieterle, P Harlow, E Hausner, F Sistare, A Thompson & J Vonderscher

]]> Novel Biomarkers of Acute Kidney Toxicity F M Goodsaid M Blank F Dieterle P Harlow E Hausner F Sistare A Thompson J Vonderscher doi:10.1038/clpt.2009.149 Clinical Pharmacology & Therapeutics 86, 490 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics August 26, 2009 10.1038/clpt.2009.149 http://dx.doi.org/10.1038/clpt.2009.149 86 5 490 496 http://dx.doi.org/10.1038/clpt.2009.149 Population Analyses of Atorvastatin Clearance in Patients Living in the Community and in Nursing Homes http://feeds.nature.com/~r/clpt/rss/current/~3/A3Mp2_ke5Fg/clpt.2009.100 Population Analyses of Atorvastatin Clearance in Patients Living in the Community and in Nursing Homes

Clinical Pharmacology & Therapeutics 86, 497 (November 2009). doi:10.1038/clpt.2009.100

Authors: J B Schwartz & D Verotta

]]> Population Analyses of Atorvastatin Clearance in Patients Living in the Community and in Nursing Homes J B Schwartz D Verotta doi:10.1038/clpt.2009.100 Clinical Pharmacology & Therapeutics 86, 497 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 1, 2009 10.1038/clpt.2009.100 http://dx.doi.org/10.1038/clpt.2009.100 86 5 497 502 http://dx.doi.org/10.1038/clpt.2009.100 Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies http://feeds.nature.com/~r/clpt/rss/current/~3/PnMBSIwiiXw/clpt.2009.34 Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies

Clinical Pharmacology & Therapeutics 86, 503 (November 2009). doi:10.1038/clpt.2009.34

Authors: C Fosser, G Duczynski, M Agin, P Wicker & B Darpo

]]> Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies C Fosser G Duczynski M Agin P Wicker B Darpo doi:10.1038/clpt.2009.34 Clinical Pharmacology & Therapeutics 86, 503 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics April 1, 2009 10.1038/clpt.2009.34 http://dx.doi.org/10.1038/clpt.2009.34 86 5 503 506 http://dx.doi.org/10.1038/clpt.2009.34 Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses http://feeds.nature.com/~r/clpt/rss/current/~3/bLvLIh7gGSU/clpt.2009.103 Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses

Clinical Pharmacology & Therapeutics 86, 507 (November 2009). doi:10.1038/clpt.2009.103

Authors: A P Chiang & A J Butte

]]> Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses A P Chiang A J Butte doi:10.1038/clpt.2009.103 Clinical Pharmacology & Therapeutics 86, 507 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 1, 2009 10.1038/clpt.2009.103 http://dx.doi.org/10.1038/clpt.2009.103 86 5 507 510 http://dx.doi.org/10.1038/clpt.2009.103 Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects http://feeds.nature.com/~r/clpt/rss/current/~3/3j1Zjbz8bPg/clpt.2009.145 Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects

Clinical Pharmacology & Therapeutics 86, 511 (November 2009). doi:10.1038/clpt.2009.145

Authors: K A Kim, W K Song & J Y Park

]]> Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects K A Kim W K Song J Y Park doi:10.1038/clpt.2009.145 Clinical Pharmacology & Therapeutics 86, 511 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics August 19, 2009 10.1038/clpt.2009.145 http://dx.doi.org/10.1038/clpt.2009.145 86 5 511 518 http://dx.doi.org/10.1038/clpt.2009.145 Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies http://feeds.nature.com/~r/clpt/rss/current/~3/dctdtG-uBCY/clpt.2009.141 Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies

Clinical Pharmacology & Therapeutics 86, 519 (November 2009). doi:10.1038/clpt.2009.141

Authors: W C Zamboni, S Strychor, L Maruca, S Ramalingam, B A Zamboni, H Wu, D M Friedland, R P Edwards, R G Stoller, C P Belani & R K Ramanathan

]]> Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies W C Zamboni S Strychor L Maruca S Ramalingam B A Zamboni H Wu D M Friedland R P Edwards R G Stoller C P Belani R K Ramanathan doi:10.1038/clpt.2009.141 Clinical Pharmacology & Therapeutics 86, 519 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics August 12, 2009 10.1038/clpt.2009.141 http://dx.doi.org/10.1038/clpt.2009.141 86 5 519 526 http://dx.doi.org/10.1038/clpt.2009.141 Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease http://feeds.nature.com/~r/clpt/rss/current/~3/vB-XKHHBbIs/clpt.2009.121 Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease

Clinical Pharmacology & Therapeutics 86, 527 (November 2009). doi:10.1038/clpt.2009.121

Authors: C Pizzi, S Mancini, L Angeloni, F Fontana, L Manzoli & G M Costa

]]> Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease C Pizzi S Mancini L Angeloni F Fontana L Manzoli G M Costa doi:10.1038/clpt.2009.121 Clinical Pharmacology & Therapeutics 86, 527 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 29, 2009 10.1038/clpt.2009.121 http://dx.doi.org/10.1038/clpt.2009.121 86 5 527 532 http://dx.doi.org/10.1038/clpt.2009.121 Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order http://feeds.nature.com/~r/clpt/rss/current/~3/VcG5IfQEgj0/clpt.2009.101 Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order

Clinical Pharmacology & Therapeutics 86, 533 (November 2009). doi:10.1038/clpt.2009.101

Authors: J A Johnson, Y Gong, K R Bailey, R M Cooper-DeHoff, A B Chapman, S T Turner, G L Schwartz, K Campbell, S Schmidt, A L Beitelshees, E Boerwinkle & J G Gums

]]> Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order J A Johnson Y Gong K R Bailey R M Cooper-DeHoff A B Chapman S T Turner G L Schwartz K Campbell S Schmidt A L Beitelshees E Boerwinkle J G Gums doi:10.1038/clpt.2009.101 Clinical Pharmacology & Therapeutics 86, 533 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 1, 2009 10.1038/clpt.2009.101 http://dx.doi.org/10.1038/clpt.2009.101 86 5 533 539 http://dx.doi.org/10.1038/clpt.2009.101 Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy http://feeds.nature.com/~r/clpt/rss/current/~3/gjKrsUl88r0/clpt.2009.104 Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy

Clinical Pharmacology & Therapeutics 86, 540 (November 2009). doi:10.1038/clpt.2009.104

Authors: J H S You, K K N Tsui, R S M Wong & G Cheng

]]> Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy J H S You K K N Tsui R S M Wong G Cheng doi:10.1038/clpt.2009.104 Clinical Pharmacology & Therapeutics 86, 540 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 1, 2009 10.1038/clpt.2009.104 http://dx.doi.org/10.1038/clpt.2009.104 86 5 540 547 http://dx.doi.org/10.1038/clpt.2009.104 Pharmacokinetic Studies in Hemodialysis Patients http://feeds.nature.com/~r/clpt/rss/current/~3/1s0_UKQVaME/clpt.2009.147 Pharmacokinetic Studies in Hemodialysis Patients

Clinical Pharmacology & Therapeutics 86, 548 (November 2009). doi:10.1038/clpt.2009.147

Authors: A J Atkinson & J G Umans

]]> Pharmacokinetic Studies in Hemodialysis Patients A J Atkinson J G Umans doi:10.1038/clpt.2009.147 Clinical Pharmacology & Therapeutics 86, 548 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics August 12, 2009 10.1038/clpt.2009.147 http://dx.doi.org/10.1038/clpt.2009.147 86 5 548 552 http://dx.doi.org/10.1038/clpt.2009.147 The Influence of Chronic Renal Failure on Drug Metabolism and Transport http://feeds.nature.com/~r/clpt/rss/current/~3/HuG-YCKpXN8/clpt.2009.163 The Influence of Chronic Renal Failure on Drug Metabolism and Transport

Clinical Pharmacology & Therapeutics 86, 553 (November 2009). doi:10.1038/clpt.2009.163

Author: A W Dreisbach

]]> The Influence of Chronic Renal Failure on Drug Metabolism and Transport A W Dreisbach doi:10.1038/clpt.2009.163 Clinical Pharmacology & Therapeutics 86, 553 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics September 23, 2009 10.1038/clpt.2009.163 http://dx.doi.org/10.1038/clpt.2009.163 86 5 553 556 http://dx.doi.org/10.1038/clpt.2009.163 Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment http://feeds.nature.com/~r/clpt/rss/current/~3/BjvfteYKQs0/clpt.2009.182 Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment

Clinical Pharmacology & Therapeutics 86, 557 (November 2009). doi:10.1038/clpt.2009.182

Authors: R L Lalonde & J A Wagner

]]> Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment R L Lalonde J A Wagner doi:10.1038/clpt.2009.182 Clinical Pharmacology & Therapeutics 86, 557 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics September 23, 2009 10.1038/clpt.2009.182 http://dx.doi.org/10.1038/clpt.2009.182 86 5 557 561 http://dx.doi.org/10.1038/clpt.2009.182 The Impact of Continuous Renal Replacement Therapy on Drug Therapy http://feeds.nature.com/~r/clpt/rss/current/~3/zni3wJCNaLc/clpt.2009.152 The Impact of Continuous Renal Replacement Therapy on Drug Therapy

Clinical Pharmacology & Therapeutics 86, 562 (November 2009). doi:10.1038/clpt.2009.152

Author: G M Susla

]]> The Impact of Continuous Renal Replacement Therapy on Drug Therapy G M Susla doi:10.1038/clpt.2009.152 Clinical Pharmacology & Therapeutics 86, 562 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics September 2, 2009 10.1038/clpt.2009.152 http://dx.doi.org/10.1038/clpt.2009.152 86 5 562 565 http://dx.doi.org/10.1038/clpt.2009.152 Public Health Consequences of Chronic Kidney Disease http://feeds.nature.com/~r/clpt/rss/current/~3/ZQCq3DDWGjQ/clpt.2009.137 Public Health Consequences of Chronic Kidney Disease

Clinical Pharmacology & Therapeutics 86, 566 (November 2009). doi:10.1038/clpt.2009.137

Author: D E Weiner

]]> Public Health Consequences of Chronic Kidney Disease D E Weiner doi:10.1038/clpt.2009.137 Clinical Pharmacology & Therapeutics 86, 566 (November 2009) 2009-10-20 Clinical Pharmacology & Therapeutics July 29, 2009 10.1038/clpt.2009.137 http://dx.doi.org/10.1038/clpt.2009.137 86 5 566 569 http://dx.doi.org/10.1038/clpt.2009.137